NASDAQ:DMPI - DelMar Pharmaceuticals, Inc.
$0.40
 $0.01
+3.63%
1:40PM EDT
2019-02-15
DelMar Pharmaceuticals, Inc., incorporated on June 24, 2009, is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications.VAL-083 represents a small molecule chemotherapeutic approved for the treatment of cancer. As of June 30, 2016, VAL-083 had been assessed in 42 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI) in the United States as a treatment against various cancers, including lung, brain, cervical, ovarian tumors and leukemia. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  DMPI     avg for
industry  
  avg for
sector  
42 stocks weight:  12. 92   0. 00   0. 00  
42 stocks rank:  3. 85 K 1. 86 K 1. 09 K
# analyst opinions:  1. 00   14. 92   14. 43  

quick ratio:  3. 62   5. 37   1. 81  
current ratio:  4. 39   5. 69   2. 19  

target price low:  0. 38   88. 97   117. 82  
target price avg:  0. 38   115. 19   141. 96  
target price high:  0. 38   143. 40   163. 16  
1-yr high:  1. 23   124. 30   142. 77  
last close:  0. 39   101. 85   127. 84  
50-day avg:  0. 41   98. 27   122. 46  
200-day avg:  0. 62   99. 72   122. 70  
1-yr low:  0. 32   78. 19   100. 16  
volume:  100. 92 K 2. 38 M 4. 64 M
50-day avg volume:  87. 35 K 3. 31 M 4. 94 M
200-day avg volume:  123. 92 K 3. 23 M 4. 28 M

1-day return:  0. 00 % 0. 22 % 0. 48 %
this week return:  -4. 88 % 1. 77 % 2. 01 %
12-wk return:  -29. 73 % 6. 56 % 3. 33 %
52-wk return:  -68. 45 % -2. 23 % 14. 35 %

enterprise value (EV):  11. 73 M 55. 17 B 104. 51 B
market cap:  8. 80 M 49. 01 B 96. 46 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -10. 63 M 2. 37 B 3. 58 B

shares outstanding:  22. 56 M 607. 99 M 1. 22 B
shares:  19. 91 M 605. 53 M 1. 15 B
shares short:  637. 12 K 11. 62 M 12. 55 M
shares short prior month:  773. 70 K 11. 95 M 13. 44 M
short ratio:  5. 91   4. 82   3. 10  
short % of float:  3. 04 % 6. 19 % 2. 82 %
total cash/share:  0. 17   12. 02   11. 46  
total cash:  3. 88 M 7. 41 B 7. 37 B
free cash flow:  -5. 67 M 95. 99 M 2. 04 B
operating cash flow:  -9. 56 M 164. 74 M 3. 04 B

book value:  -0. 12   14. 43   28. 26  
price/book:  -3. 25   -1. 57   -2. 97  
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -16. 18 % --- ---
1-yr mean volatility:  -0. 39 % 0. 01 % 0. 06 %

1-yr EPS:  -0. 47   3. 03   4. 09  
forward EPS:  -0. 54   4. 33   6. 99  
P/E:  -0. 84   6. 11   26. 91  
forward P/E:  -0. 77   8. 38   10. 48  
PE/G:  0. 02   0. 37   5. 61  
growth:  -51. 38 % 683. 72 % 104. 79 %
earnings high:  -0. 00   1. 27   1. 66  
earnings avg:  -0. 00   1. 01   1. 53  
earnings low:  -0. 00   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -68. 37 % -3. 27 % 3. 81 %
return on equity:  -126. 15 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  1. 07   1. 21   0. 93  
sharpe (1yr):  -1. 32   0. 06   0. 98  

held % insiders:  8. 66 % 6. 46 % 3. 21 %
held % institutions:  6. 98 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : DMPI
.    + 0.157 =         0.157 :: INITIAL WEIGHT
.  + 537.419 =       537.577 :: inverse volume-to-price addition
.  + 174.372 =       711.949 :: spline projection addition
.  - 188.743 =       523.206 :: poor performance penalty
.    x 0.563 =       294.666 :: one-year gains+dividend factor
.    x 3.877 =      1142.309 :: 13 weeks' performance factor
.    x 1.492 =      1704.883 :: industry recommendation factor
.    x 0.993 =      1693.227 :: return on assets factor
.    x 0.987 =      1671.866 :: return on equity factor
.     x 2.77 =      4631.644 :: current ratio factor
.    x 1.176 =      5445.697 :: quick ratio factor
.    x 1.081 =       5888.42 :: short ratio factor
.    x 1.968 =     11585.466 :: price-to-book factor
.    x 2.172 =     25165.082 :: P/E weight
.    x 2.209 =     55588.637 :: PE/G factor
.    x 1.549 =     86124.875 :: beta factor
.    x 0.572 =     49299.747 :: sharpe factor
.    x 0.986 =     48592.421 :: target low factor
.    x 0.975 =     47356.705 :: target mean factor
.    x 0.986 =     46677.257 :: target high factor
.    x 1.066 =     49739.882 :: industry 12-weeks return
.    x 0.865 =     43029.709 :: "drift" penalty 2 days ago
.    x 0.991 =     42646.966 :: overall "drift" factor
.     x 0.85 =     36249.921 :: largest single-day jump factor
.     x 0.06 =      2159.019 :: low price factor
.      x 1.0 =      2159.163 :: factor hist industry gain for week 06
.   cubeRoot =        12.925 :: reduced for readability
.                     12.925 :: FINAL WEIGHT for NASDAQ:DMPI


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org